Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data - Report - MDSpire

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • By

  • Igor Snast

  • Yuliya Valdman-Grinshpoun

  • Naji Bathish

  • Hagit Matz

  • Yuri Shclar

  • Sari Murad

  • Tali Czarnowicki

  • Eran Shavit

  • Liuqing Yang

  • Sandra Goss

  • Inbal Piller Maor

  • Assaf Halperin

  • Shiran Naftalberg Blonder

  • Raanan Cohen

  • Alex Bleterman

  • Moran Barak

  • Lev Pavlovsky

  • March 31, 2026

  • 0 min

Share

Clinical Report: Efficacy, Quality of Life Improvement, and Longevity of Risankizumab

Overview

The PRIMMA study demonstrates that risankizumab significantly improves quality of life, reduces pruritus, and enhances work productivity in patients with moderate-to-severe psoriasis over 52 weeks. Notably, 58% of participants achieved a Dermatology Life Quality Index score of 0/1, indicating substantial quality of life improvements.

Background

Moderate-to-severe psoriasis is a chronic condition that severely impacts patients' physical and psychosocial well-being. Effective management is crucial as pruritus and other symptoms can lead to significant impairment in quality of life. The introduction of biologic therapies like risankizumab offers new avenues for achieving better patient outcomes, but real-world evidence on their effectiveness is essential for guiding treatment decisions.

Data Highlights

Outcome MeasureResults
DLQI 0/158%
Low Pruritus (PNRS 0-3)81%
sPGA 0/177%
Improvement in Sleep and Work ProductivitySignificant
Nocturnal Scratch DurationSignificantly Reduced

Key Findings

  • 58% of patients achieved a DLQI score of 0/1 after 52 weeks of treatment.
  • 81% reported low pruritus (PNRS 0-3) at the end of the study.
  • 77% reached a static PGA score of 0/1, indicating minimal disease activity.
  • Improvements were observed in sleep quality and work productivity.
  • Digital monitoring showed a significant reduction in nocturnal scratching duration.

Clinical Implications

The findings underscore the importance of integrating patient-reported outcomes and objective measures in managing moderate-to-severe psoriasis. Clinicians should consider risankizumab as a viable treatment option for improving quality of life and reducing symptom burden in affected patients.

Conclusion

Risankizumab demonstrates significant efficacy in enhancing quality of life and reducing pruritus in patients with moderate-to-severe psoriasis. The integration of digital monitoring tools may further optimize treatment strategies.

References

  1. Clinical Rheumatology, 2018 -- Effectiveness of Certolizumab Pegol With and Without Disease-Modifying Anti-Rheumatic Drugs Over Four Years in Patients with Psoriatic Arthritis
  2. Clinical Rheumatology, 2021 -- Evaluating the Impact of Treatment on Domains Related to Psoriatic Arthritis
  3. Clinical Rheumatology, 2022 -- Assessment of ixekizumab's safety and effectiveness in active psoriatic arthritis patients
  4. Drug Safety, 2024 -- Evaluating the Tolerability of Ixekizumab in Chinese Adults Suffering from Moderate-to-Severe Plaque Psoriasis
  5. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris
  6. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis
  7. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis
  8. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris
  9. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis
  10. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results - PubMed

Original Source(s)

Efficacy, Quality of Life Improvement, and Longevity of Risankizumab in Individuals with Moderate-to-Severe Psoriasis: Insights from the PRIMMA Study's Real-World Data

  • by Igor Snast, Yuliya Valdman-Grinshpoun, Naji Bathish, Hagit Matz, Yuri Shclar, Sari Murad, Tali Czarnowicki, Eran Shavit, Liuqing Yang, Sandra Goss, Inbal Piller Maor, Assaf Halperin, Shiran Naftalberg Blonder, Raanan Cohen, Alex Bleterman, Moran Barak, Lev Pavlovsky

  • March 31, 2026

Related Content

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial